Literature DB >> 11524474

Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multisystem disorder.

C M Wilson1, G M Grace, D G Munoz, B P He, M J Strong.   

Abstract

BACKGROUND: Traditionally considered a motor neuron-selective disorder, the clinical manifestations of ALS can include a frontotemporal dementia. Although the pathologic substrate of cognitive impairment remains to be defined, the presence of ubiquitin-immunoreactive (Ub+) intraneuronal inclusions in cortical regions has been suggested to constitute a pathologic marker of this process.
METHODS: The authors compared the neuropathological features of four cognitively impaired patients with ALS, four cognitively intact patients with ALS, and four neurologically normal patients. The extent and load of Ub+ neuronal inclusions, Ub+ dystrophic neurites, and superficial linear spongiosis (SLS) was determined among a number of cortical, hippocampal, and subcortical regions.
RESULTS: Although Ub+, alpha-synuclein-negative, and tau-negative neuronal inclusions were observed in both cognitively impaired and cognitively intact patients with ALS, their density and extent was greater among the former, with the difference greatest in the cingulate gyrus. Ub+ neurites were observed in a similar distribution. Only the presence of SLS, affecting the first and second cortical layers, reliably distinguished between the cognitively impaired and cognitively intact ALS subpopulations. In three of four cognitively impaired patients with ALS, SLS was associated with transcortical microglial activation, in the absence of detectable differences in astrocytosis, density of calbindin or parvalbumin neurons, or optical density of synaptophysin and SNAP-25.
CONCLUSIONS: Although intraneuronal Ub+ inclusions and dystrophic neurites are observed in both ALS subpopulations, the presence of cognitive impairment was associated with a greater distribution and load of both neuropathologic features, suggesting a disease continuum. Moreover, cognitive impairment was uniformly associated with superficial linear spongiosis, a pathologic feature common to several forms of frontotemporal dementia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524474     DOI: 10.1212/wnl.57.4.651

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-01-01       Impact factor: 17.088

2.  Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability.

Authors:  F Agosta; E Pagani; M A Rocca; D Caputo; M Perini; F Salvi; A Prelle; M Filippi
Journal:  Hum Brain Mapp       Date:  2007-12       Impact factor: 5.038

3.  Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study.

Authors:  F Agosta; E Pagani; M Petrolini; D Caputo; M Perini; A Prelle; F Salvi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-15       Impact factor: 3.825

Review 4.  The frontotemporal syndromes of ALS. Clinicopathological correlates.

Authors:  Michael Joseph Strong; Wencheng Yang
Journal:  J Mol Neurosci       Date:  2011-08-02       Impact factor: 3.444

Review 5.  The relationship between amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  George M Ringholz; Scott R Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

6.  Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study.

Authors:  U Usman; C Choi; R Camicioli; P Seres; M Lynch; R Sekhon; W Johnston; S Kalra
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-21       Impact factor: 3.825

7.  Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis.

Authors:  D M Mezzapesa; A Ceccarelli; F Dicuonzo; A Carella; M F De Caro; M Lopez; V Samarelli; P Livrea; I L Simone
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

Review 8.  Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review.

Authors:  Maria Teresa Giordana; Patrizia Ferrero; Silvia Grifoni; Alessia Pellerino; Andrea Naldi; Anna Montuschi
Journal:  Neurol Sci       Date:  2010-10-16       Impact factor: 3.307

9.  Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients.

Authors:  Herbert Schreiber; Tanja Gaigalat; Ursula Wiedemuth-Catrinescu; Michael Graf; Ingo Uttner; Rainer Muche; Albert Christian Ludolph
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

10.  Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.

Authors:  Jordi A Matías-Guiu; Vanesa Pytel; María Nieves Cabrera-Martín; Lucía Galán; María Valles-Salgado; Antonio Guerrero; Teresa Moreno-Ramos; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.